预防或延缓糖尿病的减肥生活方式与药物治疗
Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes.
作者信息
Price Stephanie, Le Quynh Nhu, White Nicole D
机构信息
Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska.
出版信息
Am J Lifestyle Med. 2017 Nov 9;12(1):34-37. doi: 10.1177/1559827617740825. eCollection 2018 Jan-Feb.
Abstract
Preventing or delaying the conversion of prediabetes to overt diabetes can reduce mortality and morbidity rates, improve health-related quality of life, and reduce other comorbid complications associated with diabetes. Studies have shown that a modest weight loss is one strategy for preventing or delaying diabetes diagnosis. First-line therapy in preventing progression of prediabetes to overt diabetes is weight loss through lifestyle modifications; however, pharmacotherapy for weight loss may be initiated if lifestyle alone is ineffective. The purpose of this article is to describe the pharmacotherapeuptic options for weight loss that can be used in conjunction with lifestyle in the prevention or delay of diabetes in patients with prediabetes.
摘要
预防或延缓糖尿病前期转化为显性糖尿病可降低死亡率和发病率，改善健康相关生活质量，并减少与糖尿病相关的其他合并症。研究表明，适度减重是预防或延缓糖尿病诊断的一种策略。预防糖尿病前期进展为显性糖尿病的一线治疗方法是通过生活方式改变来减重；然而，如果仅靠生活方式干预无效，则可启动减重药物治疗。本文旨在描述可与生活方式相结合用于预防或延缓糖尿病前期患者发生糖尿病的减重药物治疗选择。
相似文献
1
Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes.预防或延缓糖尿病的减肥生活方式与药物治疗
Am J Lifestyle Med. 2017 Nov 9;12(1):34-37. doi: 10.1177/1559827617740825. eCollection 2018 Jan-Feb.
2
Controversies in prediabetes: do we have a diagnosis?糖尿病前期的争议：我们有诊断吗？
Postgrad Med. 2012 Jul;124(4):109-18. doi: 10.3810/pgm.2012.07.2562.
3
Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.体重减轻与生活方式治疗、药物治疗和减重手术预防和治疗 2 型糖尿病：作用机制。
Curr Obes Rep. 2015 Jun;4(2):287-302. doi: 10.1007/s13679-015-0155-x.
4
ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES.抗肥胖药物治疗与预防从糖尿病前期进展为2型糖尿病的潜力
Endocr Pract. 2015 Jun;21(6):634-44. doi: 10.4158/EP14460.RA. Epub 2015 Feb 25.
5
What are the pharmacotherapy options for treating prediabetes?治疗前期糖尿病的药物治疗选择有哪些？
Expert Opin Pharmacother. 2014 Oct;15(14):2003-18. doi: 10.1517/14656566.2014.944160. Epub 2014 Aug 19.
6
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).体重减轻诱导的前驱糖尿病缓解的机制：随机、对照、多中心前驱糖尿病生活方式干预研究（PLIS）的事后分析。
Lancet Diabetes Endocrinol. 2023 Nov;11(11):798-810. doi: 10.1016/S2213-8587(23)00235-8. Epub 2023 Sep 25.
7
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.当前和新兴的用于糖尿病前期和糖尿病患者体重管理的药物治疗。
Can J Diabetes. 2015 Dec;39 Suppl 5:S134-41. doi: 10.1016/j.jcjd.2015.10.001.
8
Prediabetes diagnosis and treatment: A review.糖尿病前期的诊断与治疗：综述
World J Diabetes. 2015 Mar 15;6(2):296-303. doi: 10.4239/wjd.v6.i2.296.
9
A 12-Month Follow-Up of the Effects of a Digital Diabetes Prevention Program (VP Transform for Prediabetes) on Weight and Physical Activity Among Adults With Prediabetes: Secondary Analysis.一项数字糖尿病预防计划（糖尿病前期的VP转变计划）对糖尿病前期成年人体重和身体活动影响的12个月随访：二次分析
JMIR Diabetes. 2022 Jan 14;7(1):e23243. doi: 10.2196/23243.
10
Current and emerging pharmacotherapy for prediabetes: are we moving forward?当前和新兴的糖尿病前期药物治疗：我们是否在前进？
Expert Opin Pharmacother. 2018 Oct;19(15):1663-1673. doi: 10.1080/14656566.2018.1517155. Epub 2018 Sep 10.
引用本文的文献
1
Family Involvement to Stop the Conversion of Prediabetes to Diabetes.家庭参与预防糖尿病前期转化为糖尿病
Korean J Fam Med. 2023 Nov;44(6):303-310. doi: 10.4082/kjfm.23.0019. Epub 2023 Aug 14.
2
root decreases lipid accumulation through the induction of lipolysis and thermogenesis via AMPK activation in 3T3‑L1 cells.根通过激活 AMPK 诱导脂肪分解和生热来减少 3T3-L1 细胞中的脂质积累。
Int J Mol Med. 2023 Aug;52(2). doi: 10.3892/ijmm.2023.5268. Epub 2023 Jun 16.
3
Greater and More Focused Measures Are Needed to Tackle Diabetes and Obesity Epidemics in the Nations of the Gulf Cooperation Council.海湾合作委员会国家需要采取更有力、更具针对性的措施来应对糖尿病和肥胖症流行问题。
Int J Endocrinol. 2021 Mar 26;2021:6661346. doi: 10.1155/2021/6661346. eCollection 2021.
本文引用的文献
1
Response to Comment on American Diabetes Association. . Diabetes Care 2017;40(Suppl. 1):S1-S135.对关于美国糖尿病协会评论的回应。《糖尿病护理》2017年；40（增刊1）：S1 - S135。
Diabetes Care. 2017 Jul;40(7):e94-e95. doi: 10.2337/dci17-0007.
2
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法（2017年执行摘要）的共识声明。
Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.
3
Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia.氯卡色林对糖尿病前期进展为2型糖尿病及恢复正常血糖的评估。
Postgrad Med. 2016 May;128(4):364-70. doi: 10.1080/00325481.2016.1178590.
4
Long-term drug treatment for obesity: a systematic and clinical review.长期药物治疗肥胖：系统评价和临床综述。
JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361.
5
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.纳曲酮缓释/安非他酮缓释联合疗法对超重和肥胖2型糖尿病患者体重及血糖参数的影响
Diabetes Care. 2013 Dec;36(12):4022-9. doi: 10.2337/dc13-0234. Epub 2013 Oct 21.
6
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.使用缓释苯丁胺和托吡酯治疗的糖尿病前期和代谢综合征患者2型糖尿病的预防。
Diabetes Care. 2014 Apr;37(4):912-21. doi: 10.2337/dc13-1518. Epub 2013 Oct 8.
7
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.糖尿病预防计划结局研究中二甲双胍的长期安全性、耐受性和体重减轻。
Diabetes Care. 2012 Apr;35(4):731-7. doi: 10.2337/dc11-1299.
8
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.糖尿病预防计划结果研究中糖尿病发病率和体重减轻的10年随访
Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29.
9
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.赛尼可预防肥胖受试者糖尿病（XENDOS）研究：一项关于奥利司他作为肥胖患者生活方式改变辅助手段预防2型糖尿病的随机研究。
Diabetes Care. 2004 Jan;27(1):155-61. doi: 10.2337/diacare.27.1.155.
10
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.通过生活方式干预或二甲双胍降低2型糖尿病的发病率。
N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
Zotero 插件